Vitamin B 12 , also known as cobalamin (Cbl), is a micronutrient that is synthesised only by microorganisms, yet is essential to human health. Cobalamin was first isolated by Smith (Ref. 1) and Rickes (Ref. 2), after Minot and Murphy (Ref. 3) showed that pernicious anaemia could be treated with oral liver extract. Later, vitamin B 12 deficiency as a result of genetic disease was described despite adequate vitamin intake (Ref. 4). Some patients responded successfully to very high doses of vitamin B 12 , suggesting blocks in vitamin processing. These patients had homocystinuria and/or methylmalonic aciduria, implicating dysfunctional methionine synthase (MS) and/or methylmalonyl-CoA mutase (MUT or MCM). We now know that blocks in the intracellular processing of cobalamin into cofactor forms, methylcobalamin (MeCbl) for MS and adenosylcobalamin (AdoCbl) for MCM, or in the functional activity of MS or MCM result in inborn errors. These genetic blocks may be devastating in newborns or in early childhood. Understanding the genes, gene products and subcellular transport of vitamin B 12 is important for minimising the disease burden from these disorders. This review outlines the present knowledge of cobalamin metabolism, with a focus on steps related to the intracellular human pathway and the initial cataloguing of cobalamin-utilisation disorders into complementation groups and biochemically distinct classes. Key to these discoveries have been the hundreds of patients who have been the source of cell cultures and DNA samples that have given us our current understanding of vitamin B 12 utilisation in humans.
Vitamin B 12 structure
The structure of cobalamin was first solved by Hodgkin (Ref. 5) using x-ray crystallography. It is a large organometallic molecule, ∼1300-1500 Da in size, and is the most chemically complex vitamin known. The focal point of vitamin B 12 is the central cobalt atom, which has up to six ligands bound to it. Four of the ligands are the nitrogen atoms of the planar corrin ring that surround the cobalt atom (Fig. 1) . The α-axial ligand, extending below the corrin ring, is a nitrogen of the 5,6-dimethylbenzimidazole (DMB) phosphoribosyl moiety that also attaches back to the corrin ring through one of its propionamide side chains. The upper or β-axial ligand varies, depending on the modification state of cobalamin (R-group in Fig. 1a ). Functional β-axial ligands are methyl (MeCbl) or 5 ′ -deoxyadenosyl (AdoCbl) groups. Additionally, a hydroxyl group (OHCbl) or a cyano group (CNCbl) can be bound as physiologically relevant β-axial ligands.
There are three important, inter-related factors that contribute to cobalamin reactivity and function: the oxidation state of cobalt; whether the DMB is coordinated to cobalt in the lower axial position; and the identity of the R-group bound in the upper axial position. The cobalt atom of cobalamin may exist in the +3 [cob(III)alamin], +2 [cob(II)alamin] or +1 [cob(I)alamin] oxidation state. AdoCbl, MeCbl, CNCbl and OHCbl, all of which are cob(III)alamins, prefer to adopt a configuration where the DMB nitrogen base is coordinated to the cobalt in the lower axial position (referred to as 'base-on') ( Fig. 1) . Some enzymes, however, are able to shift these cob(III)alamins to the 'base-off' configuration. Interestingly, MS and MCM, which use MeCbl and AdoCbl as cofactors, respectively, bind the cobalamin so that the DMB nitrogen is displaced from the cobalt and replaced by a histidine of the enzyme (Fig. 1b) . This type of binding is considered 'base-off/His-on' and is important for the catalytic activity of the enzymes. Cob(II)alamin generally has no R-group bound, binding only DMB as the lower axial ligand to make its preferred five-coordinate state. However, in the presence of ATP, MMAB, the human adenosyltransferase (ATR) enzyme, is able to bind cob(II)alamin in a novel four-coordinate state, where neither axial position is occupied (Ref. 51) . Cob(I)alamin usually has no axial ligand. It is a highly reactive nucleophile that very easily oxidises to cob(II)alamin (Ref. 52) . The challenge to the cell is how to productively produce cob(I)alamin, as in the reaction cycle of MS, without exposing the local environment to nucleophillic attack and risk of free-radical damage. The nature of the axial ligands also affects the ease with which the central cobalt is reduced. Strongly coordinating ligands stabilise cobalt against reduction, whereas weakly coordinating ligands allow cobalt to be reduced more easily (Ref. 53) . Base-on cobalamin falls into the former category, protecting the cobalt from reduction because DMB has greater electron-donating character than the H 2 O molecule that binds in its absence (Ref. 54 ).
Vitamin B 12 origins
Vitamin B 12 is an extremely old molecule in evolution. It has even been suggested that B 12 was synthesised prebiotically (Ref. 55 ). Accordingly, vitamin B 12 utilisation is dispersed throughout evolution, occurring in both Eukaryota and Prokaryota, perhaps having been passed on from the 'breakthrough organism' -the last organism to use RNA as the sole genetically encoded catalyst (Ref.  56 ). Interestingly, although cobalamin utilisation is distributed widely among phyla, cobalamin synthesis seems limited to only a select few Archaea and Eubacteria. Perhaps this is because the synthesis of cobalamin is so complexinvolving in excess of 25 steps, which can proceed either aerobically (cob genes) or anaerobically (cbi genes) (Ref. 57) . Therefore, although mammals and other higher organisms require vitamin B 12 for life, they ostensibly acquire it from their prokaryotic counterparts. Another interesting facet of the evolution of cobalamin is that vitamin B 12 users seem more scattered than logically spread out through evolution, with whole phyla sometimes gaining or losing vitamin B 12 dependency (Ref. 58) . Additionally, although mammals and other higher eukaryotes are restricted to two cobalamin-dependent enzymes, MS and MCM, prokaryotes use a plethora of enzymes requiring this cofactor. These enzymes include three classes of AdoCbl-dependent mutases, the isomerases (e.g. MCM, ribonucleotide reductase, glutamate mutase), the eliminases (e.g. diol dehydratase) and the aminomutases (e.g. Dlysine-5,6-aminomutase), as well as the MeCbl-dependent methyltransferases (e.g. MS) and the vitamin B 12 -dependent reductive dehalogenases (e.g. 3-6 chloro-4-hydroxybenzoate dehalogenase) (Refs 59, 60). Therefore, because higher eukaryotes share common vitamin B 12 ancestry with prokaryotes, but have apparently limited use of the vitamin and no biosynthesis, prokaryotes in general and a few specific bacteria and Archaea in particular have proved to be very useful models to understand vitamin B 12 metabolism.
Human vitamin B 12 ingestion and absorption
Because vitamin B 12 is made by only a few microorganisms, it is acquired through dietary uptake in animals. Human dietary sources include milk, eggs, fish and meat in quantities in excess of a few micrograms a day (Ref. 61) . In humans, the absorption, transport and cellular uptake of cobalamin is complex. Food-bound cobalamin is released in the stomach with the help of peptic activity, where it is subsequently The 'R group' corresponds to substitutions at the upper or β-axial ligand (5 ′ -deoxyadenosyl-, methyl-, hydroxo-, cyano-). The dimethylbenzimidazole constituent (DMB) is shown coordinated to the cobalt in the lower α-axial position ('base-on' structure). DMB is linked to the corrin ring through a phosphoribosyl attached to a propionamide side chain. (b) Structure of methylcobalamin (MeCbl) with DMB displaced from the cobalt by a histidine residue in methionine synthase (MS; the 'baseoff/His-on' structure). A similar configuration is observed for adenosylcobalamin (AdoCbl) bound to methylmalonyl-CoA mutase. Structures are from http://www.genome.jp using the 'SIMCOMP Search' utility (query C00576, vitamin B 12 ; C06410, MeCbl-MS). Initially, four distinct complementation groups were identified, cblA-cblC and mut. However, over the years, the method came to be used diagnostically with hundreds of cell lines being analysed, mainly in the McGill University laboratory of David Rosenblatt, which became a dominant diagnostic centre using these techniques. So far, eight complementation groups, cblA-cblG and mut, have been described that have blocks in the production or utilisation of MeCbl, AdoCbl or both cofactors. Although all the genes corresponding to these disorders have now been described, many of their functions remain unclear. Figure 2 illustrates the known or predicted functional location of the protein products of these genes. Three complementation groups -cblF, cblC and cblD -correspond to blocks in steps that are common to the synthesis of both cofactors with resulting deficiency of MS and MCM activities. Patients from these groups have combined homocystinuria and methylmalonic aciduria. Three groups, cblD variant 1, cblE and cblG, have blocks in the cytosolic pathway leading to MeCbl synthesis or apo-MS and result in deficient MS activity and Cobalamin intermediates are in red. Excreted metabolites due to genetic defects are in shaded boxes. Pathway details are described in the text. In the lysosome, cobalamin is released from transcobalamin (TC) through its degradation (arrow pointing to dots). In the cytosol, R groups are released by the cblC protein with the cob(II)alamin [Cob(II)] product remaining bound (dotted line emanating from the cblC protein denotes complex with cobalamin forms). The three versions of the cblD protein (cblD, cblD-1, cblD-2) illustrate the role of the protein in directing cobalamin to the mitochondrial or cytosolic pathway. In the mitochondrion, the cblB protein adds the 5 ′ -deoxyadenosyl group, generating the active cofactor [adenosylcobalamin (AdoCbl)], which is transferred to the mut [methylmalonyl-CoA mutase (MCM)] protein.
The cblA protein is proposed to act as a gatekeeper to ensure that the cofactor form that is accepted and retained by MCM is AdoCbl. In the cytosolic pathway, cob(II)alamin is bound to the cblG [methionine synthase (MS) (Fig. 3) . The most common is the c.271dupA mutation, which causes a frameshift truncation, accounting for 42% of pathogenic alleles (Ref. 14). Additionally, the c.394C > T (R132X) and c.331C > T (R111X) mutations are found commonly, at 20% and 5% of alleles, respectively. Although all cblC patients have combined homocystinuria and methylmalonic aciduria and often have haemotological, neurological and ophthalmic abnormalities to some degree, they tend to fall into either of two distinct phenotypes correlating with age of onset (Ref. 86) . Earlyonset patients present in the first year of life with severe disease and rarely respond clinically to treatment, whereas late-onset patients present in childhood to adulthood, are more likely to have less severe symptoms, and usually respond better to treatment (Ref. 86) . A strong genotype-phenotype correlation can be found with some mutations: the c.271dupA and c.331C > T (R111X) mutations usually cause the much more prevalent early-onset disease, whereas some missense mutations [e.g. c.482G > A (R161Q)] and, bewilderingly, the c.394C > T (R132X) nonsense mutation usually result in late-onset disease (Refs 14, 15 Mutations in the genes underlying the defects of the eight complementation groups Expert Reviews in Molecular Medicine © Cambridge University Press 2010 . These results suggest that MMACHC might be involved in intracellular cobalamin transport and reductive dealkylation or decyanation, perhaps interacting with the cblF protein for export of cobalamin out of the lysosome and beginning the initial processing of cobalamin, yielding cob(II)alamin, before passing it along for distribution to the rest of the pathway (Refs 14, 62) (Fig. 2) 2) . These results suggested that the cblD protein might be responsible for branching of the cobalamin metabolism pathways to the cytosolic or mitochondrial compartments (Fig. 2) (Fig. 3) . Transfection experiments 6, 7, 8, 9, 10 demonstrated correction of the defect in mutant fibroblasts. In particular, a cDNA constructed with a 5 ′ -truncation mutation could correct the synthesis of MeCbl, suggesting that an internal translation initiation site is probably functional. Additionally, they demonstrated that the cblH complementation group, which had been previously described for one patient with unidentified methylmalonic aciduria (Ref. 97) , was actually an example of cblD variant 2 (Fig. 2) (Fig. 3) The corresponding human reducing system proved to be encoded by a single gene, MTRR, which is mutated in cblE patients (Fig. 3) The human gene, named MMAA, was identified in a search for genes clustered in proximity to MCM (mut) in microbial genomes and while searching for orthologous sequences in the human genome (Ref. 6). Examination of the sequence of MMAA, however, revealed that it did not encode a reductase, but rather a protein that belonged to the G3E family of P-loop GTPases, a group of proteins that participate in the assembly or function of the metal centres in metalloenzymes (Ref. 6). More than 30 cblA patient mutations have been described in the MMAA gene, with most of them corresponding to nonsense or frameshift mutations (Fig. 3) . Although most cblA patients present in infancy or childhood with methylmalonic aciduria and potentially life-threatening acidotic crises (Ref. 123) . Most of the mutations identified in cblB disease were found to cluster in exon 7, which encodes the active site of the enzyme (Refs 12, 132) (Fig. 3) . Several mutations have been modelled in human and microbial ATRs, identifying defects in substrate or cofactor binding, active site functions or protein dynamics (Refs 132, 133, 134, 135, 136) . Interestingly, two of the mutations (R186W, E193K) resulted in absent protein in western blots of patient cell extracts, suggesting protein instability as a major contributor to disease phenotype (Ref. (Fig. 3) . Two distinct classes of mutations have been described: mut − ('mut-minus'), when there is residual enzyme activity or detectable [ 14 C] propionate incorporation by mutant fibroblasts; and mut 0 ('mut-zero'), when protein or enzyme activity is not detected, as found, for example, in frameshift or chain-terminating mutations and some amino-acid substitutions (Refs 139, 140) . Unsurprisingly, these two groups separate patients clinically. mut 
Model for the intracellular processing of vitamin B 12
The genes and proteins corresponding to all eight complementation groups defined in patients have provided most of the elements required to describe the intracellular processing of vitamin B 12 (Fig. 2) 148, 149, 150) .
Although we have gained much insight into the pathway of vitamin B 12 metabolism, the goal of the medical geneticist has been to gain insight into managing the vitamin B 12 disorders, providing access to carrier testing and prenatal diagnosis, and, in the best of outcomes, preventing or successfully treating symptomatic disease. The remarkable feature of vitamin B 12 utilisation disorders has been their potential for treatment. The discovery that high-dose vitamin B 12 can overcome pathway deficits in some patients has given new life to individuals with an otherwise potentially severe or fatal disease. The early discovery that OHCbl is effective in the treatment of cblC disorder while CNCbl is not is a powerful illustration of the complexity of vitamin B 12 biochemistry. The more recent finding that AdoCbl or MeCbl may have a significant stabilising effect on MMACHC protein, despite ultimately being hydrolysed to cob(II)alamin, reminds us that there is still much to be learned on behalf of the patient. Strikingly, the most recent success with gene therapy to treat mice with knockout of the Mut gene (Ref. 151) has opened up a new avenue for treatment that might ultimately benefit patients with metabolically 'unresponsive' disorders. The application of widespread newborn screening for homocysteine and methylmalonate underscores the opportunity to identify and treat these patients before the onset of potentially irreversible disease. 
